Ally Bridge Group is a healthcare investment firm seeking to back scientific breakthroughs that advance the standard of care.
Since 2013, we have partnered with more than 80 biotechnology and medical technology companies, investing across private and public markets at the inflection points where clinical evidence can become commercial reality.
We invest across biotechnology and medical technology, targeting first- and best-in-class innovation with a clear path to value inflection — clinical, regulatory, or commercial.
We back clinical-stage therapies, applying scientific and regulatory expertise with the aim to advance programs through the milestones that define their value.
We back commercial-stage medical technologies, seeking to apply reimbursement and market access expertise to translate clinical success into broad adoption and durable growth.
Both strategies are built on the same thematic sector research: we form a view on where healthcare is heading, and invest behind it with conviction, not consensus.
Last-mile investments in life sciences, typically as lead investor with board representation, with the objective of advancing category-defining companies to a strategic or public market outcome.
Two dedicated strategies — Long/Short and Long-Only — investing primarily in publicly-listed biotechnology companies, grounded in the same fundamental research and sector expertise.
Breakthrough science, paired with disciplined capital and deep sector insight, can transform healthcare while creating enduring value. That conviction shapes how we invest across private and public markets.
Advance therapies and technologies that improve human health and support the companies and investors that make it possible.
A future where first- and best-in-class innovation is funded with conviction and delivers lasting impact for patients.
Integrity, discipline, agility, and conviction of purpose in every investment we make and every partnership we build.
Dedicated private and public teams, shared expertise — scientific rigor and investment discipline applied from late-stage private companies through the public markets.
We invite innovators and investors to partner with us in shaping the future of healthcare. Let’s explore how our platform can support your next stage of growth and help bring impactful solutions to more patients.